Hoechst PakistanKAR:HPL +0.08%86 EBITDA Margin % is 18.10% as of Mar. 2026, which is 72% above its 10-year median of 10.51. GuruFocus rates KAR:HPL with a GF Score™ of 86/100 and a GF Value™ of ₨3,252.20 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Hoechst Pakistan ranks better than 64.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hoechst Pakistan's EBITDA for the
three
months ended in Mar. 2026 was ₨1,394 Mil. Hoechst Pakistan's Revenue for the
three
months ended in Mar. 2026 was ₨7,699 Mil. Therefore, Hoechst Pakistan's EBITDA margin for the quarter that ended in Mar. 2026 was 18.10%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hoechst Pakistan EBITDA Margin % Related Terms
Hoechst Pakistan EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hoechst Pakistan's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HPL vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Hoechst Pakistan's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hoechst Pakistan EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hoechst Pakistan's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hoechst Pakistan's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hoechst Pakistan (KAR:HPL) has a EBITDA Margin % of 18.10% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hoechst Pakistan and its competitors. This is 72% above median its historical median of 10.51. Over the past decade, Hoechst Pakistan's EBITDA Margin % has ranged from 5.26 to 17.97. According to the industry distribution chart, Hoechst Pakistan ranks #343 out of 955 companies in the Drug Manufacturers industry, placing it in the top 35.9%.
Is Hoechst Pakistan's EBITDA Margin % too high?
Hoechst Pakistan's current EBITDA Margin % of 18.10% is 72% above median its 10-year median of 10.51. Over the past 10 years, this metric has ranged from a low of 5.26 to a high of 17.97. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Hoechst Pakistan's value of 18.10% is 46.1% above this industry median. Based on the distribution chart, Hoechst Pakistan ranks #343 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hoechst Pakistan has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hoechst Pakistan's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Hoechst Pakistan ranks #343 out of 955 companies for EBITDA Margin %. This puts Hoechst Pakistan in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Hoechst Pakistan's value of 18.10% is 46.1% above this benchmark. Historically, Hoechst Pakistan's own EBITDA Margin % has ranged from 5.26 to 17.97 over the past decade. While the company's 10-year median is 10.51 vs. the industry median of 12.39, Hoechst Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hoechst Pakistan's current EBITDA Margin % of 18.10% is 46.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hoechst Pakistan and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hoechst Pakistan's current EBITDA Margin % is 18.10%, which is 72% above median its own 10-year median of 10.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hoechst Pakistan stock overvalued right now?
Based on GuruFocus' analysis, Hoechst Pakistan (KAR:HPL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨3,252.20, compared to a current price of ₨4,015.00 — trading 23.5% above its estimated fair value. The current EBITDA Margin % is 18.10%, which is 72% above median its 10-year median of 10.51 and 46.1% above the Drug Manufacturers industry median of 12.39. Hoechst Pakistan's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hoechst Pakistan (KAR:HPL), the current EBITDA Margin % is 18.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hoechst Pakistan (KAR:HPL) Overvalued in 2026?
Based on GuruFocus' analysis, Hoechst Pakistan stock appears to be overvalued.
The current stock price of ₨4,015.00 is trading 23.5% above its estimated GF Value™ of ₨3,252.20.
GuruFocus considers Hoechst Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:HPL:
EBITDA Margin %: 18.10% (72% above median its 10-year median of 10.51)
GF Value™: ₨3,252.20 vs. price of ₨4,015.00 (23.5% above fair value)
Industry Position: 46.1% above the Drug Manufacturers median (#343 of 955)
No single metric tells the full story. See the KAR:HPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hoechst Pakistan Ltd is a healthcare company of Pakistan, focused on patient needs and engaged in the manufacturing, promotion, and sale of pharmaceutical and vaccines. The company engages in the manufacturing, selling and trading of pharmaceutical and related products.
86GF Score
Get the complete analysis for KAR:HPL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HPL has been successfully added to your 
